Business Description
Ingenia Therapeutics is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Watertown, Massachusetts, with operations in South Korea. The company focuses on developing antibody-based treatments that protect and repair small blood vessels damaged by inflammation or leakage. Its pipeline targets a range of serious conditions, including retinal diseases, glaucoma, chronic kidney disease, and cancer, all built around a proprietary platform that activates the Tie2 receptor to restore vessel health.
